 | AG0302-COVID‑19 is a COVID-19 vaccine candidate developed by AnGes Inc. This candidate followed a previous one called AG0301-COVID‑19. "Phase I/II Study... 4 KB (162 words) - 23:20, 11 November 2023 |
| original on 11 October 2020. Retrieved 14 July 2020. "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". ClinicalTrials.gov. 26 August 2020. NCT04527081. Retrieved... 98 KB (20,593 words) - 02:58, 8 March 2024 |
The COVID-19 pandemic in Nepal is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2... 181 KB (23,901 words) - 14:23, 6 January 2024 |
 | original on 11 October 2020. Retrieved 14 July 2020. "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library... 19 KB (1,376 words) - 01:09, 18 April 2024 |